Key facts
- This page summarizes John F. Ginascol's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Mar 2023, 18:36.
John F. Ginascol - 28 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- EXECUTIVE VICE PRESIDENT
- Issuer ticker
- ABT
- Reported as of
- 28 Feb 2023
- Net transaction value
- -$779,283
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2023, 18:36:37 UTC
- Prior SEC filing
- 22 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John F. Ginascol by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John F. Ginascol filed Form 4 for ABBOTT LABORATORIES (ABT) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 22 Feb 2023.
- Current net transaction value: -$779,283.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Tax liability
- Transaction value
- $684,322
- Shares
- -6,859
- Change %
- -5.4%
- Price
- $99.77
- Shares after
- 119,323
- Date
- 28 Feb 2023
- Ownership
- Direct
ABT
transaction
Common shares without par value
Sale
- Transaction value
- $94,960
- Shares
- -943
- Change %
- -0.79%
- Price
- $100.70
- Shares after
- 118,380
- Date
- 01 Mar 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).